PORTFOLIO RESPONSE

Response Analysis

Compare treatment-response results, longitudinal measurements, confidence, replicate quality, and scientific-review status across studies.

Analyses38Portfolio total

Strong Responses11Illustrative class

Partial Responses14Further validation

Needs Review7Scientist attention

Approved Results32Human sign-off

Portfolio Results

7 illustrative treatment results · select a row for scientific context

Cancer TypeStudyAssetTreatmentTimepointResponse ClassReview Status

Response Results

Human review remains distinct from illustrative response classification

Study	Asset	Cancer Model	Treatment	Timepoint	Viability	Tumour Size Change	Relative Volume	Response	Confidence	Replicate QC	Review Status
BC-001	OGC-2401	TNBC, HER2-	Control	Day 7	96%	+18%	1.18	Growth	0.96	Passed	Approved
BC-001	OGC-2401	TNBC, HER2-	Drug A	Day 7	62%	-25%	0.75	Partial Response	0.88	Passed	Approved
BC-001	OGC-2401	TNBC, HER2-	Drug B	Day 7	18%	-71%	0.29	Strong Response	0.92	Needs Review	Pending Review
GBM-004	OGC-NS-321	IDH-wildtype	Drug A	Day 7	48%	-39%	0.61	Partial Response	0.82	Needs Review	Needs Attention
LU-003	OGC-LU-104	NSCLC	Drug B	Day 7	36%	-53%	0.47	Strong Response	0.77	Failed	Needs Attention
OV-006	OGC-OV-207	High-grade serous	Drug A	Day 7	74%	-18%	0.82	Partial Response	0.89	Passed	Pending Review
PA-002	OGC-PA-084	PDAC	Drug B	Day 7	22%	-65%	0.35	Strong Response	0.91	Passed	Approved

Portfolio Treatment Comparison

Illustrative result values · selected treatment per study

Response Class Distribution

Illustrative portfolio classes

Growth5

No Response4

Partial Response14

Strong Response11

Needs Review4

Longitudinal Analysis

Day 0 → Day 3 → Day 7 · illustrative relative values

Scientific Review Queue

Human approval is a separate workflow